Enhanced anti-tumor immune responses and delay of tumor development in human epidermal growth factor receptor 2 mice immunized with an immunostimulatory peptide in poly(D,L-lactic-co-glycolic) acid nanoparticles

Diahnn F. Campbell, Rebecca Saenz, Ila S. Bharati, Daniel Seible, Liangfang Zhang, Sadik Esener, Bradley Messmer, Marie Larsson, Davorka Messmer

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Introduction: Cancer vaccines have the potential to induce curative anti-tumor immune responses and better adjuvants may improve vaccine efficacy. We have previously shown that Hp91, a peptide derived from the B box domain in high-mobility group box protein 1 (HMGB1), acts as a potent immune adjuvant. Method: In this study, Hp91 was tested as part of a therapeutic vaccine against human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Results: Free peptide did not significantly augment immune responses but, when delivered in poly(D,L-lactic-co-glycolic) acid nanoparticles (PLGA-NPs), robust activation of dendritic cells (DCs) and increased activation of HER2-specific T cells was observed in vitro. Vaccination of HER2/neu transgenic mice, a mouse breast cancer model that closely mimics the immune modulation and tolerance in some breast cancer patients, with Hp91-loaded PLGA-NPs enhanced the activation of HER2-specific cytotoxic T lymphocyte (CTL) responses, delayed tumor development, and prolonged survival. Conclusions: Taken together these findings demonstrate that the delivery of the immunostimulatory peptide Hp91 inside PLGA-NPs enhances the potency of the peptide and efficacy of a breast cancer vaccine.

Original languageEnglish (US)
Article number48
JournalBreast Cancer Research
Volume17
Issue number1
DOIs
StatePublished - Mar 31 2015
Externally publishedYes

Fingerprint

Nanoparticles
Breast Neoplasms
Peptides
Cancer Vaccines
Neoplasms
Vaccines
HMGB1 Protein
Immune Tolerance
Cytotoxic T-Lymphocytes
Dendritic Cells
Transgenic Mice
Vaccination
T-Lymphocytes
Survival
polylactic acid-polyglycolic acid copolymer
human ERBB2 protein
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Enhanced anti-tumor immune responses and delay of tumor development in human epidermal growth factor receptor 2 mice immunized with an immunostimulatory peptide in poly(D,L-lactic-co-glycolic) acid nanoparticles. / Campbell, Diahnn F.; Saenz, Rebecca; Bharati, Ila S.; Seible, Daniel; Zhang, Liangfang; Esener, Sadik; Messmer, Bradley; Larsson, Marie; Messmer, Davorka.

In: Breast Cancer Research, Vol. 17, No. 1, 48, 31.03.2015.

Research output: Contribution to journalArticle

Campbell, Diahnn F. ; Saenz, Rebecca ; Bharati, Ila S. ; Seible, Daniel ; Zhang, Liangfang ; Esener, Sadik ; Messmer, Bradley ; Larsson, Marie ; Messmer, Davorka. / Enhanced anti-tumor immune responses and delay of tumor development in human epidermal growth factor receptor 2 mice immunized with an immunostimulatory peptide in poly(D,L-lactic-co-glycolic) acid nanoparticles. In: Breast Cancer Research. 2015 ; Vol. 17, No. 1.
@article{2dd3207a8daa45a18acb656a3cee1132,
title = "Enhanced anti-tumor immune responses and delay of tumor development in human epidermal growth factor receptor 2 mice immunized with an immunostimulatory peptide in poly(D,L-lactic-co-glycolic) acid nanoparticles",
abstract = "Introduction: Cancer vaccines have the potential to induce curative anti-tumor immune responses and better adjuvants may improve vaccine efficacy. We have previously shown that Hp91, a peptide derived from the B box domain in high-mobility group box protein 1 (HMGB1), acts as a potent immune adjuvant. Method: In this study, Hp91 was tested as part of a therapeutic vaccine against human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Results: Free peptide did not significantly augment immune responses but, when delivered in poly(D,L-lactic-co-glycolic) acid nanoparticles (PLGA-NPs), robust activation of dendritic cells (DCs) and increased activation of HER2-specific T cells was observed in vitro. Vaccination of HER2/neu transgenic mice, a mouse breast cancer model that closely mimics the immune modulation and tolerance in some breast cancer patients, with Hp91-loaded PLGA-NPs enhanced the activation of HER2-specific cytotoxic T lymphocyte (CTL) responses, delayed tumor development, and prolonged survival. Conclusions: Taken together these findings demonstrate that the delivery of the immunostimulatory peptide Hp91 inside PLGA-NPs enhances the potency of the peptide and efficacy of a breast cancer vaccine.",
author = "Campbell, {Diahnn F.} and Rebecca Saenz and Bharati, {Ila S.} and Daniel Seible and Liangfang Zhang and Sadik Esener and Bradley Messmer and Marie Larsson and Davorka Messmer",
year = "2015",
month = "3",
day = "31",
doi = "10.1186/s13058-015-0552-9",
language = "English (US)",
volume = "17",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Enhanced anti-tumor immune responses and delay of tumor development in human epidermal growth factor receptor 2 mice immunized with an immunostimulatory peptide in poly(D,L-lactic-co-glycolic) acid nanoparticles

AU - Campbell, Diahnn F.

AU - Saenz, Rebecca

AU - Bharati, Ila S.

AU - Seible, Daniel

AU - Zhang, Liangfang

AU - Esener, Sadik

AU - Messmer, Bradley

AU - Larsson, Marie

AU - Messmer, Davorka

PY - 2015/3/31

Y1 - 2015/3/31

N2 - Introduction: Cancer vaccines have the potential to induce curative anti-tumor immune responses and better adjuvants may improve vaccine efficacy. We have previously shown that Hp91, a peptide derived from the B box domain in high-mobility group box protein 1 (HMGB1), acts as a potent immune adjuvant. Method: In this study, Hp91 was tested as part of a therapeutic vaccine against human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Results: Free peptide did not significantly augment immune responses but, when delivered in poly(D,L-lactic-co-glycolic) acid nanoparticles (PLGA-NPs), robust activation of dendritic cells (DCs) and increased activation of HER2-specific T cells was observed in vitro. Vaccination of HER2/neu transgenic mice, a mouse breast cancer model that closely mimics the immune modulation and tolerance in some breast cancer patients, with Hp91-loaded PLGA-NPs enhanced the activation of HER2-specific cytotoxic T lymphocyte (CTL) responses, delayed tumor development, and prolonged survival. Conclusions: Taken together these findings demonstrate that the delivery of the immunostimulatory peptide Hp91 inside PLGA-NPs enhances the potency of the peptide and efficacy of a breast cancer vaccine.

AB - Introduction: Cancer vaccines have the potential to induce curative anti-tumor immune responses and better adjuvants may improve vaccine efficacy. We have previously shown that Hp91, a peptide derived from the B box domain in high-mobility group box protein 1 (HMGB1), acts as a potent immune adjuvant. Method: In this study, Hp91 was tested as part of a therapeutic vaccine against human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Results: Free peptide did not significantly augment immune responses but, when delivered in poly(D,L-lactic-co-glycolic) acid nanoparticles (PLGA-NPs), robust activation of dendritic cells (DCs) and increased activation of HER2-specific T cells was observed in vitro. Vaccination of HER2/neu transgenic mice, a mouse breast cancer model that closely mimics the immune modulation and tolerance in some breast cancer patients, with Hp91-loaded PLGA-NPs enhanced the activation of HER2-specific cytotoxic T lymphocyte (CTL) responses, delayed tumor development, and prolonged survival. Conclusions: Taken together these findings demonstrate that the delivery of the immunostimulatory peptide Hp91 inside PLGA-NPs enhances the potency of the peptide and efficacy of a breast cancer vaccine.

UR - http://www.scopus.com/inward/record.url?scp=84928540742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928540742&partnerID=8YFLogxK

U2 - 10.1186/s13058-015-0552-9

DO - 10.1186/s13058-015-0552-9

M3 - Article

VL - 17

JO - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 1

M1 - 48

ER -